USA Equities Corp (OTCMKTS: USAQ) Signs Co-Promotion Deal With ENP Networking For Marketing and Advertising Support

USA Equities Corp (OTCMKTS: USAQ) provides primary care physicians with medical devices technology with necessary digital solutions that can help them boost proactive revenues via value-based solutions for chronic disease evaluation and treatment. The company’s products help patients save time and expenses for visiting a specialist while enabling physicians to increase revenue via current CPT reimbursement codes. USA Equities Corp offers training and software needed to improve clinical outcomes through informatics, algorithmically customized medicine for behavior-based management, remote patient monitoring, preventive medicine, and chronic care. 

USA Equities Corp (OTCMKTS: USAQ) and ENP Network recently entered a co-promotion deal. ENP is an online services provider serving various groups including nurse practitioners as well as nurse practitioner groups with more than 260,000 associates. ENP Networking offers advertising and marketing support focusing on 27,843 individual practitioners on its network. The agreement as well as the anticipated virtual Allergen Immunotherapy and University of Miami’s Miller School of Medicine Allergy Diagnostics CME event will cover AllergiEnd’s allergen immunotherapy and allergy diagnostic product offerings. Troy Grogan, the company’s CEO, said that they are delighted to work with the ENP Network to expand the company’s independent treatment provider network by leveraging ENP’s massive nurse practitioner industry experience. Grogan said that the company’s AllergiEnd allergen immunotherapy and allergy diagnostic products will offer nurse practitioners improved preventive and chronic diseases management tools for patient treatment. 

USA Equities Corp (OTCMKTS: USAQ) announced Q1 2021 financial results reporting solid sequential quarter growth and setting the stage for Q2. The company more than doubled its revenue to around $304,000, with gross margin improving to 43.9%. The growth is mainly due to the growing allergy diagnostic kits, allergen immunotherapy treatment sales, and customer base expansion. Troy Grogan, the company’s CEO, saw continued momentum in April, and they expect revenue and gross margin increase in Q2 2021.

Leave a Comment

Your email address will not be published.